Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double-blind, placebo-controlled, randomized study.

bladder pain syndrome interstitial cystitis pentosan polysulfate

Journal

Central European journal of urology
ISSN: 2080-4806
Titre abrégé: Cent European J Urol
Pays: Poland
ID NLM: 101587101

Informations de publication

Date de publication:
2021
Historique:
received: 23 11 2020
revised: 04 02 2021
accepted: 30 03 2021
entrez: 2 8 2021
pubmed: 3 8 2021
medline: 3 8 2021
Statut: ppublish

Résumé

Bladder pain syndrome/interstitial cystitis (BPS/IC) is a condition that is characterized by urgency, frequency and/or pelvic pain. The disease occurs mainly in women. BPS/IC can be severe enough to have a significant impact on patients' quality of life, but it can also be associated with moderate symptoms that are equally debilitating.The aim of this article was to evaluate the possibility of the use of pentosan polysulfate sodium in patients in the complex treatment of BPS/IC. A multicenter, double-blind, placebo-controlled, randomized study was conducted in parallel groups in 7 Russian medical centers. Efficacy and safety have been established as the main criteria. A total of 93 patients were screened. Statistical analysis was performed. It has been shown that pentosan therapy is more effective than in the placebo. Average change in the number of points on the scale O'Leary-Santa Interstitial Cystitis Symptom Index compared to baseline data in the pentosan group 4.93 ±3, 03, in the placebo group 1.66 ±3.19 (p = 0.014), and the adverse events and safety of pentosan are comparable to the placebo group. Oral glycosaminoglycan (pentosan polusulfate sodium) is an effective and safe drug and should be included in the complex treatment of patients with bladder pain syndrome/interstitial cystitis.

Identifiants

pubmed: 34336239
doi: 10.5173/ceju.2021.0340.R1
pii: 0340.R1
pmc: PMC8318027
doi:

Types de publication

Journal Article

Langues

eng

Pagination

201-207

Informations de copyright

Copyright by Polish Urological Association.

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Urology. 2000 Dec 20;56(6):940-5
pubmed: 11113737
J Urol. 1993 Sep;150(3):845-8
pubmed: 7688432
J Urol. 2003 Sep;170(3):810-5
pubmed: 12913705
Can Fam Physician. 2000 Dec;46:2430-4, 2437-40
pubmed: 11153410
J Urol. 2000 May;163(5):1434-9
pubmed: 10751852
J Urol. 1987 Sep;138(3):503-7
pubmed: 2442415
Urology. 1997 Jul;50(1):39-43
pubmed: 9218016
J Urol. 1987 Sep;138(3):513-6
pubmed: 2442417
J Urol. 2000 Aug;164(2):423-7
pubmed: 10893601
Urology. 1990 Jun;35(6):552-8
pubmed: 1693797
Curr Opin Obstet Gynecol. 2000 Oct;12(5):405-10
pubmed: 11111883
J Urol. 2008 Jan;179(1):177-85
pubmed: 18001798
J Urol. 2015 Mar;193(3):857-62
pubmed: 25245489
J Urol. 1999 Feb;161(2):549-52
pubmed: 9915446

Auteurs

George Kasyan (G)

Department of Urology, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Russian Federation.
City Clinical Hospital n.a. S.I. Spasokukotsky, Moscow Health Department, Moscow, Russian Federation.

Yury Kupriyanov (Y)

Department of Urology, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Russian Federation.
City Clinical Hospital n.a. S.I. Spasokukotsky, Moscow Health Department, Moscow, Russian Federation.

Alexander Karasev (A)

Department of Urology, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Russian Federation.

Kirill Baibarin (K)

Pride-Pharma, Moscow, Russia.

Dmitry Pushkar (D)

Department of Urology, A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Russian Federation.
City Clinical Hospital n.a. S.I. Spasokukotsky, Moscow Health Department, Moscow, Russian Federation.

Classifications MeSH